    Heinrich Dreismann | | ZoomInfo.com    Heinrich Dreismann | Myriad Genetics , Inc. | ZoomInfo.com

Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version















MYGN Heinrich Dreismann Insider Trades for Myriad Genetics Inc.


































Bulletin






Investor Alert







New York Markets Open in:



Market Snapshot
Analyst Ratings


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Myriad Genetics Inc.

                  NASDAQ: MYGN
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Myriad Genetics Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 27, 2017, 4:58 p.m.


MYGN

/quotes/zigman/58124/composite


$
23.46




Change

-0.0028
-0.01%

Volume
Volume 103,764
Quotes are delayed by 20 min








/quotes/zigman/58124/composite
Previous close

$
			23.74
		


$
				23.46
			
Change

-0.28
-1.18%





Day low
Day high
$23.34
$23.98










52 week low
52 week high

            $15.15
        

            $32.54
        


















Insider Activity


Individual




Heinrich Dreismann



Dr. Heinrich Dreismann is Independent Director at Interpace Diagnostics Group, Inc., Independent Director at Ignyta, Inc., Independent Director at Myriad Genetics, Inc., Lead Independent Director at Singulex, Inc., a Member at American Society for Microbiology, a Member at European Diagnostic Manufacturers Association and a Member at New York Academy of Sciences. He is on the Board of Directors at Interpace Diagnostics Group, Inc., Ignyta, Inc., AdvanDx, Inc., Adarza BioSystems, Inc., Spinomix SA, HistoRx, Inc., Myriad Genetics, Inc., Sirius Genomics, Inc., Singulex, Inc., Magellan Diagnostics, Inc., Iconix Biosciences, Inc., GeneNews Ltd., BioCision LLC, BioHelix Corp., Celula, Inc. and Stratos Genomics, Inc. Dr. Dreismann was previously employed as Independent Director by Med BioGene, Inc., Chief Executive Officer by FasTraq, Inc., Chief Executive Officer by Vectrant Technologies, Inc., Head-Global Business Development by Roche Diagnostics, President & Chief Executive Officer by Roche Molecular Systems, Inc., and Executive Chairman by Homestead Clinical Corp. He also served on the board at Shrink Nanotechnologies, Inc., Nanogen, Inc., ChondroGene Ltd. and Oxford BioDynamics Ltd. He received his graduate degree from the University of Münster and a doctorate degree from the University of Münster.



Transactions


Date
Shares
Transaction
Value





12/01/2016
15,024


 
Award at $0 per share.


0


12/03/2015
7,500


 
Award at $0 per share.


0


11/05/2015
30,000


 
Disposition at $44.44 per share.


1,333,200


11/05/2015
30,000


 
Derivative/Non-derivative trans. at $27.61 per share.


828,300


11/05/2015
30,000


 
Disposition at $44.44 per share.


1,333,200


11/05/2015
30,000


 
Derivative/Non-derivative trans. at $25.39 per share.


761,700


12/04/2014
10,000


 
Award at $0 per share.


0


02/18/2014
30,000


 
Disposition at $35 per share.


1,050,000


02/18/2014
30,000


 
Derivative/Non-derivative trans. at $21.29 per share.


638,700


05/10/2013
30,000


 
Disposition at $31.16 per share.


934,800


05/10/2013
30,000


 
Derivative/Non-derivative trans. at $18.05 per share.


541,500





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Mark C. Capone 
President, Chief Executive Officer & Director




Mr. Gary A. King 
Executive Vice President-International Operations




Mr. R. Bryan Riggsbee 
Chief Financial Officer, Treasurer & Executive VP




Mr. Robert Gardner Harrison 
Chief Information Officer




Dr. Jerry S. Lanchbury 
Chief Scientific Officer




Mr. Richard S. Swartz 
Executive Vice President




Ms. Nicole  Lambert 
General Manager-Urology Business Unit




Ms. Vicki  Fish 
General Manager-Dermatology




Mr. Scott  Gleason 
Investor Relations Contact




Mr. Ronald S. Rogers 
EVP-Corporate Communications & Media Contact




Ms. Jayne B. Hart 
Executive Vice President-Human Resources




Mr. Richard M. Marsh 
Secretary, Executive VP & General Counsel




Dr. John Tannahill Henderson 
Chairman




Dr. Walter A. Gilbert 
Vice Chairman




Mr. Lawrence C. Best 
Independent Director




Ms. S. Louise Phanstiel 
Independent Director




Dr. Heinrich  Dreismann 
Independent Director




Dr. Dennis H. Langer 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




8:02 AM EDT
July 28, 2017


/marketstate/country/us
New York

	Pre


/marketstate/country/uk
London

	Open


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
8:02aExxonMobil Q2 revenue $62.9 bln vs $57.7 bln
8:02aStarbucks shares sink, but analysts are optimistic about future growth
8:01aExxonMobil Q2 EPS 78 cents vs. 41 cents
8:01aMeet the ‘Hamilton’ actors who play up to 18 roles in the hit show
8:00aAmazon stock price target raised to $1,175 from $1,110 at J.P. Morgan
7:59aPlantronics downgraded to neutral from overweight at J.P. Morgan
7:58aQEP Resources stock price target cut to $9 from $11 at J.P. Morgan
7:58aQEP Resources downgraded to neutral from overweight at J.P. Morgan
7:57aRenaissanceRe stock price target cut to $145 from $165 at J.P. Morgan
7:57aXL Group stock price target raised to $52 from $45 at J.P. Morgan
7:57aAbbVie shares surge 2% on Q2 profit, revenue beats
7:56aRenaissanceRe downgraded to neutral from overweight at J.P. Morgan
7:56aXL Group upgraded to overweight from neutral at J.P. Morgan
7:54aStarbucks stock price target cut to $62 from $63 at J.P. Morgan
7:53aGoodyear Tire's stock dives after slashed profit outlook offsets in-line earnings
7:52aWatch out: ‘Kids’ are making the most money in this stock market 
7:51aStock market set to extend fresh tech rout as Amazon disappoints; GDP data ahead
7:49aShares of video game maker Activision Blizzard down more than 1% 
7:49aIntel earnings have message for AMD and Nvidia: ‘Bring it on’
7:48aAaron's shares up nearly 6% in Friday premarket trading
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,796.55

+85.54
+0.39%





nasdaq

/quotes/zigman/12633936/realtime
6,382.19

-40.56
-0.63%





s&p 500

/quotes/zigman/3870025/realtime
2,475.42

-2.41
-0.10%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15
























































Heinrich Dreismann Ph.D.: Executive Profile & Biography - Bloomberg









































  





















































































July 28, 2017 8:02 AM ET
Biotechnology

Company Overview of Ignyta, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Heinrich   Dreismann Ph.D.Director, Ignyta, Inc.AgeTotal Calculated CompensationThis person is connected to 12 Board Members in 12 different organizations across 25 different industries.See Board Relationships64$178,469
Background

		Dr. Heinrich Dreismann, also known as Heiner, Ph.D. has been the Chief Executive Officer of Vectrant Technologies Inc. since 2006. Dr. Dreismann was a Venture Partner at SV Life Sciences Advisers, LLC since 2011. He joined SV Life Sciences Advisers on October 5, 2011. He was part of the biotechnology team and focused on In Vitro Diagnostics, diagnostics, biotechnology, biopharmaceuticals, medical devices and instrumentation and healthcare services. He served as the Head ... of Diagnostics at MetaStat, Inc. since October 2013 and served as its Diagnostic Consultant from October 2013 to August 4, 2016. He served as an Interim Chief Executive Officer of GeneNews Limited from May 31, 2008 to July 12, 2013. He served as an Executive Advisor at Ignyta, Inc. since January 2012. He had a successful career at the Roche Group from 1985 to 2006. He served as the Chief Executive Officer and President of Roche Molecular Systems (RMS) Inc., from 1985 to 2006. He co-founded Integrated Diagnostics Inc. in 2005 and served as its Executive Chairman. Dr. Dreismann served as the President of Roche Molecular Systems Inc. since January 2001 and as its Chief Executive Officer from 2000 to 2006 and oversaw significant expansion of its product portfolio. He held a number of additional positions at Roche Diagnostics Corporation, including Head of Global Business Development, Head of Business Unit of PCR Europe since 1991, Head of Business unit Microbiology and Vice President of Manufacturing as well as R&D positions in microbiology and infectious diseases and in manufacturing and served as Business Unit Manager of PCR and Microbiology. He served as Head of Integration Office of Roche Diagnostics, where he managed the merger of Boehringer Mannheim at Roche Diagnostics. In his last role at RMS, he oversaw the doubling of the molecular in vitro diagnostics business to over $1 billion and had overall responsibilities for business, corporate and R&D functions, as well as the respective staff. He led the introduction of PCR-based tests in Europe as early as 1992 and witnessed firsthand the industry growth over the last two decades. He is a veteran of the molecular diagnostics industry and has a wealth of experience and contacts. Dr. Dreismann is a seasoned executive with more than 28 years of experience in the health care industry and is regarded as a pioneer in the early adoption of the polymerase chain reaction (PCR) technique. He serves as the Chairman of the Board at Spinomix SA. Dr. Dreismann serves as the Chairman of Optimal Medicine Ltd. He served as the Chairman of TheraGenetics Ltd., and Smart Holograms Limited. He served as the Chairman of Business Advisory Board at Shrink Nanotechnologies, Inc. He serves on the boards of several innovative public and private diagnostic companies. He has been a Director of Ignyta, Inc. since October 31, 2013. Dr. Dreismann has been a Director of Magellan Diagnostics, Inc. since August 2007, Celula, Inc., since 2009. Dr. Dreismann has been a Director at Myriad Genetics, Inc., since June 2010. He serves as a Director of MedCision, Inc., Stratos Genomics Inc., BioCision, LLC, BioHelix Corporation, Vectrant Technologies and AlliedPath. He has been an Independent Director of AdvanDx, Inc. since March 27, 2013. He has been a Director of Singulex, Inc. since January 2007 and serves as its Lead Independent Director. He has been Member of Business Advisory Board at 3D Signatures Inc. since October 2016. He served as a Director of Adarza BioSystems, Inc. He served as a Lead Director of GeneNews Limited from May 31, 2008 to November 4, 2016 and its Independent Director from September 19, 2006 to November 4, 2016. He served as a Director of Shrink Nanotechnologies, Inc. from June 22, 2009 to November 1, 2011. He served as a Director of Integrated Diagnostics Inc. He served as a Director of Interpace Diagnostics Group, Inc. since August 13, 2014 until September 30, 2016. He served as a Director of Sirius Genomics Inc. since November 2008. He served as a Director at Med BioGene Inc. from May 29, 2008 to September 5, 2014 and Iconix Biosciences, Inc. since October 24, 2006. He served as a Director of HistoRx, Inc. since October 2010 and Oxford BioDynamics Plc (OxFord BioDynamics Limited) since October 2008. He served as a Director of Ngen, Inc. from October 31, 2006 to August 2009. He served as a Member of Business Advisory Board at Shrink Nanotechnologies, Inc. Dr. Dreismann has a Post-Doctoral Fellowship from the French Center for Nuclear Research in Saclay, near Paris, France. Dr. Dreismann did his Post-Doctoral studies in microbial genetics at the Centre d'Etudes Nucleaires de Saclay, France. Dr. Dreismann holds M.S. Degree in Biology from Westfaelische Wilhelms University, Muenster and a Ph.D. in Microbiology/Molecular Biology from Westfaelische Wilhelms University, Muenster (summa cum laude) in 2014.Read Full Background




Corporate Headquarters
4545 Towne Centre CourtSan Diego, California 92121United StatesPhone: 858-255-5959Fax: --
Board Members Memberships
DirectorBioCision, LLCDirectorBiohelix CorporationDirectorStratos Genomics, Inc.ChairmanSpinomix SADirectorMedCision, Inc2007-PresentLead Independent DirectorSingulex, Inc.2007-PresentDirectorMagellan Diagnostics, Inc.2009-PresentDirectorCelula, Inc.2010-PresentDirectorMyriad Genetics, Inc.2013-PresentIndependent DirectorAdvanDx, Inc.2013-PresentDirectorIgnyta, Inc.
Education
MS Westfälische Wilhelms-Universität MünsterPhD 2014Westfälische Wilhelms-Universität Münster
Other Affiliations
Iconix Biosciences, Inc.Myriad Genetics, Inc.Ngen, Inc.Interpace Diagnostics Group, Inc.SV Health Investors, LLCGeneNews LimitedRoche Diagnostics CorporationRoche Molecular Systems Inc.Westfälische Wilhelms-Universität MünsterAdvanDx, Inc.Smart Holograms LimitedHistoRx, Inc.Singulex, Inc.Magellan Diagnostics, Inc.Sirius Genomics Inc.Med BioGene Inc.Integrated Diagnostics Inc.TheraGenetics Ltd.Celula, Inc.Adarza BioSystems, Inc.Oxford BioDynamics PlcBioCision, LLCShrink Nanotechnologies, Inc.Biohelix CorporationStratos Genomics, Inc.MetaStat, Inc.Spinomix SA3D Signatures Inc.MedCision, Inc


Annual Compensation
				There is no Annual Compensation data available.
				Stocks Options
				There is no Stock Options data available.
				Total Compensation
Total Annual Cash Compensation$57,500Total Calculated Compensation$178,469




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONThere is no Competitor Compensation data available.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Ignyta, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close




























Heinrich Dreismann, PhD - Biography

















































































Log in






E-mail



Password







Remember




Forgot password ?









Become a member for free
Sign up





Sign up




New memberSign up for FREE


New customerDiscover our portfolios












 United States
 United Kingdom
 France
 Deutschland
 Schweiz (DE)
 Suisse (FR)










Settings

            Dynamic quotes 


OFFON

















Markets
Equities
North AmericaEuropeAsiaOceaniaMiddle East» More Equities

Indexes
DOW JONESS&P 500NASDAQ 100TSX COMPFTSE 100» More Indexes

Currency / Forex
EUR / USDGBP / USDUSD / JPYUSD / CADAUD / USD» More Currencies

Commodities
GOLDCrude Oil (WTI)Crude Oil (BRENT)SILVERPLATINUM» More Commodities


 News
Latest News
CompaniesMarketsEconomyCurrency / ForexCommoditiesInterest RatesBusiness LeadersFinancial calendarEconomic calendar

Listed company
Analyst reco.RumorsIPOsCapital Markets TransactionsNew ContractsProfits warningsAppointmentsPress ReleasesEventsCorporate actions

Sector News
EnergyBasic MaterialsIndustrialsConsumer CyclicalConsumer Non-CyclicalFinancialsHealthcareTechnologyTelecommunications ServicesUtilities


 Analysis
All AnalysisCommentariesIndex AnalysisStock Trading StrategiesCommodity AnalysisForex Analysis

 Stock Picks
All stock picks

 Portfolios
My Portfolio
Virtual portfolios
4-Traders Portfolios
European PortfolioUSA PortfolioAsian Portfolio


 Screeners
Market Screener HomeFundamental Analyse
Top Investor RatingTop Trading RatingTop ConsensusGrowth stocksYield stocksLow valuations

Technical Analysis
Oversold stocksOverbought stocksClose to resistancesClose to supportsAccumulation phaseMost volatile stocks


 Watchlists
My Watchlists
Watchlists
Top Lists
Yield stocksGrowth stocksUndervalued Stocks


 Top / Flop
Top News
Most Read NewsHot News

Top Fundamentals
Top CapitalizationTop YieldTop PERTop ConsensusTop Fundamentals

Top Technicals
Top RSIUnusual volumesTop GapsTop STIM

Top Movers
Top USATop CanadaTop U.K.Top GermanyTop EuropeTop Asia


 Tools
Market ScreenerDynamic chartFinancial calendarEconomic calendarSector researchCurrency converter

 Our Services
Premium AccessDiscover our Services

 



















 






4-Traders Homepage  >  News  >  Business Leaders  >  Business Leaders Biography


Business Leaders




Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors HomeAll newsMost read newsBusiness Leaders Biography


 
















Heinrich Dreismann, PhD

Age : 63Public asset : 840,420 USDLinked companies :  Myriad Genetics, Inc. -  Ignyta Inc 





Summary 



Dr. Heinrich Dreismann is a Member at American Society for Microbiology, a Member at European Diagnostic Manufacturers Association and a Member at New York Academy of Sciences.He is on the Board of Directors at Ignyta, Inc., AdvanDx, Inc., Adarza BioSystems, Inc., Spinomix SA, HistoRx, Inc., Myriad Genetics, Inc., Singulex, Inc., BioCision LLC, Celula, Inc., Magellan Biosciences, Inc., Novellusdx Ltd., Nucleix Ltd. and Stratos Genomics, Inc. Dr. Dreismann was previously employed as an Independent Director by Interpace Diagnostics Group, Inc., an Independent Director by Med BioGene, Inc., Chief Executive Officer by FasTraq, Inc., Lead Director by GeneNews Ltd., Chief Executive Officer by Vectrant Technologies, Inc., Head-Global Business Development by Roche Diagnostics, President & Chief Executive Officer by Roche Molecular Systems, Inc., and Executive Chairman by Homestead Clinical Corp.He also served on the board at Sirius Genomics, Inc., Shrink Nanotechnologies, Inc., Magellan Diagnostics, Inc., Ngen, Inc., Iconix Biosciences, Inc., BioHelix Corp., ChondroGene Ltd. and Oxford BioDynamics Plc.He received his graduate degree from the University of Münster and a doctorate degree from the University of Münster.



Current positions of Heinrich Dreismann, PhD 









 NameTitle
Since
 Myriad Genetics, Inc.(Advanced Medical Equipment & Technology)
Independent Director
2010 Ignyta Inc(Biotechnology & Medical Research)
Independent Director
2013Singulex, Inc.
Director
2007BioCision LLC
Director
-HistoRx, Inc.
Director
2010Celula, Inc.
Director
-AdvanDx, Inc.
Director
2012Adarza BioSystems, Inc.
Director
2011Stratos Genomics, Inc.
Director
-Nucleix Ltd.
Director
-Spinomix SA
Director
2011Magellan Biosciences, Inc.
Director
-Novellusdx Ltd.
Director
-New York Academy of Sciences
Member
-American Society for Microbiology
Member
-European Diagnostic Manufacturers Association
Member
-



Holdings of Heinrich Dreismann, PhD 










 NameEquities%Valuation

 Myriad Genetics, Inc. (MYGN) Advanced Medical Equipment & Technology 32,5240.048%840,420 USD
 GeneNews Ltd (GEN) Biotechnology & Medical Research 00.0000%0 USD
 Ignyta Inc (RXDX) Biotechnology & Medical Research 00.0000%0 USD



Heinrich Dreismann, PhD: Personal Network 







 NameLinked companies

Dennis H. Langer Myriad Genetics, Inc.AdvanDx, Inc. 

Rajiv Indravadan Modi American Society for MicrobiologyNew York Academy of Sciences 

Stephen L. Rose Stratos Genomics, Inc.Singulex, Inc. 

Erez Chimovits Novellusdx Ltd.Nucleix Ltd. 

Jerry S. Lanchbury Myriad Genetics, Inc. 

Richard M. Marsh Myriad Genetics, Inc. 

Jonathan E. Lim Ignyta Inc 

Mark C. Capone Myriad Genetics, Inc. 

James L. Freddo Ignyta Inc 

Robert Gardner Harrison Myriad Genetics, Inc. 




Most Read News 




07/21DJMUKESH AMBANI : Reliance's Ambani Launches Low-Cost Mobile Phone for India



07/21DJINDRA NOOYI : PepsiCo 'Stretches' Managers At Top -- WSJ



07/27 LI KA-SHING : Li Ka-shing's CKI to buy German energy metering firm Ista



07/26DJBERNARD ARNAULT : LVMH's Profit Rises 24% in First Half



07/27 RUPERT MURDOCH : As Murdoch waits, Sky cuts operating costs to protect profits



07/26DJMEG WHITMAN : Meg Whitman Steps Down From HP Board



07/26DJDAVID SIMON : Executive Pay Falls for Big Mall Owners as Retail Storm Rages On



07/27DJJEFF BEZOS : Amazon's Jeff Bezos Becomes World's Richest Person



01:16pDJELON MUSK : Top Company News of the Day



07/22DJWILBUR ROSS : More Cross-Border Commerce



More news

 


            © 2017 People and Ownership :    









Advertisement








Heinrich Dreismann, PhD : Connections 



 Pernix Therapeutics Holdings Inc









Dennis H. Langer




 Novavax, Inc.









Rajiv Indravadan Modi




 Novus Therapeutics Inc









Erez Chimovits




 Dicerna Pharmaceuticals Inc









Dennis H. Langer




 Ignyta Inc









Jonathan E. LimJames L. Freddo




 Myriad Genetics, Inc.









Dennis H. LangerJerry S. LanchburyRichard M. MarshMark C. CaponeRobert Gardner Harrison




 Gujarat Alkalies & Chemicals Limited









Rajiv Indravadan Modi




Nucleix Ltd.
                                            








Erez Chimovits





Stratos Genomics, Inc.
                                            








Stephen L. Rose





Braeburn Pharmaceuticals, Inc.
                                            








Dennis H. Langer





Sancilio Pharmaceuticals Co., Inc.
                                            








Dennis H. Langer





Sirna Therapeutics, Inc.
                                            








Dennis H. Langer





OrbiMed Capital LLC
                                            








Erez Chimovits





Georgetown University School of Medicine
                                            








Dennis H. Langer





Novellusdx Ltd.
                                            








Erez Chimovits





Cadila Pharmaceuticals Ltd.
                                            








Rajiv Indravadan Modi





American Society for Microbiology
                                            








Rajiv Indravadan Modi





Targeted Microwave Solutions, Inc.
                                            








Rajiv Indravadan Modi





Senet, Inc.
                                            








Stephen L. Rose





Ignyta Operating, Inc.
                                            








Jonathan E. Lim





 







Popular Business Leaders 


 

Bernard Arnault
Mary Barra
Jeff Bezos
Lloyd Blankfein
Michael Bloomberg
Yannick Bolloré
Warren Buffett
Jean-paul Clozel
Gary Cohn
Jamie Dimon
Ralph Dommermuth
Sebastian Ebel
John Edwards
David Einhorn
Jeff Fettig
Mark Fields
Carlos Ghosn
Terry Gou
David Henry
Carl Icahn
Li Ka-shing
Michel Landel
Daniel Loeb
Jack Ma
Lakshmi Mittal
Rupert Murdoch
Elon Musk
Peter Nicholas
John Paulson
Nelson Peltz
Georges Plassat
Hasso Plattner
Thomas Rabe
Giuseppe Recchi
Wolfgang Reitzle
Wilbur Ross
Charles Schwab
Igor Sechin
Masayoshi Son
Pascal Soriot
George Soros
Rupert Stadler
Bernard Tapie
Patrick Thomas
Tim Westergren
John Williamson
Thomas Wilson
Dieter Zetsche
Mark Zuckerberg



A-Z Business Leaders




 



























4-traders.com :MarketsNewsAnalysisStock PicksPortfoliosScreenersWatchlistsTop / FlopToolsOur ServicesAbout :Surperformance SASContact usAdvertiseLegal informationsAbout usStay Connected :FacebookTwitterPartners :Börse: Aktien, Kurse und NachrichtenBest tweets 




   Copyright © 2017 Surperformance. All rights reserved.  












 














Slave

































Heinrich Dreismann and Harry Glorikian | GenomeWeb


















Skip to main content



 







 





 









RSS Feeds
Twitter
LinkedIn
 





 







Log in




Join now


 






Business & PolicyBusiness News
Research Funding
Policy & Legislation
Regulatory News
Reimbursement

TechnologyMicroarrays & Multiplexing
PCR
Informatics
Sequencing
Mass Spec
Sample Prep
Gene Silencing/Gene Editing

ResearchGenetic Research
Gene Expression Research
Epigenetics Research
Proteomics & Protein Research
Cell Biology Research

DiagnosticsMolecular Diagnostics
Companion Diagnostics
Biomarker Discovery & Validation
Drug Discovery & Development
Clinical Sequencing
Clinical Proteomics

Disease AreasCancer
Infectious Disease
Cardiovascular Disease
Neurological & Psychological Disease
Metabolic Disease
Autoimmune Disease
Inherited Disease
Reproductive Health

Applied Markets
ResourcesWebinars
White Papers
The Scan
Career Blog
Job Listings
New Products
People in the News
Conferences & Events


Main menu 






Enter your keywords 





 





Home » Resources » People in the News » Heinrich Dreismann and Harry Glorikian 

















Heinrich Dreismann and Harry Glorikian

Oct 07, 2016

 



In a filing with the US Securities and Exchange Commission, Interpace Diagnostics announced the resignations of Heinrich Dreismann and Harry Glorikian from the company's board of directors. The company stated that neither resignation was due to a disagreement with the company or matters relating to the company's operations, policies, or practices.


 



More Like This









Jul 28, 2017


Cynthia Bens

Cynthia Bens will join the Personalized Medicine Coalition as vice president of public policy on August 21. Bens comes to PMC after more than a decade with the Alliance for Aging Research where she helped advocate for policies, including the 21st Century Cures Act, the Prescription Drug User Fee Act, and FDA’s Patient-Focused Drug Development initiative. Prior to that, she spent four years at the bipartisan government affairs firm the Loeffler Group and also worked as a staff assistant on Capitol Hill.


 











Jul 26, 2017


Rohit Khanna

Waters said in a filing with the US Securities and Exchange Commission this week that Rohit Khanna has resigned from his position as SVP, Applied Technology, effective July 21, 2017. Khanna will continue to serve as an SVP of the company and as a member of the firm's executive committee until his retirement on Dec. 31, 2017. 


 











Jul 26, 2017


Scott Howell

Tenet Diagnostics has appointed Scott Howell its CMO. He was most recently executive medical director at Heritage Provider Network. He also continues to practice at Kaiser Permanente Los Angeles Medical Center in the addiction medicine department. He was previously national senior medical director and chief medical officer Network and Population Health, Optim Insight, regional CMO Northeast region of Americhoice, and national medical director of managed care for AIDS Healthcare Foundation. 


 











Jul 26, 2017


Gene DeFelice, Alexandra Snyder

Adaptive Biotechnologies has appointed Gene DeFelice to senior vice president and general counsel and Alexandra Snyder to translational medicine lead for Adaptive Research.DeFelice has served as general counsel for several public healthcare and technology companies, including as primary counsel at Roche Diagnostics. He will join Adaptive's executive team to implement a legal infrastructure for clinical applications of next-generation sequencing technologies.Snyder has joined Adaptive from Memorial Sloan Kettering Cancer Research Center where she specialized in tumor immunogenomics and response to checkpoint blockade immunotherapy.  


 











Jul 24, 2017


Kieran Murphy, Stephen Kanovsky

Kieran Murphy has resigned from the board of NeoGenomics following his appointment as president and CEO of GE Healthcare. NeoGenomics said in a document filed with the US Securities and Exchange Commission that Murphy resigned due to the time demands of his new job, and added that it has appointed Stephen Kanovsky to fill Murphy's position on the board. He is general counsel of GE unit Global Innovation of GE Healthcare.


 











Jul 21, 2017


Thomas Loewald

Thomas Loewald, senior vice president and chief commercial officer at Thermo Fisher Scientific since early 2016, will resign from the company, effective September 1. He joined the firm's Explosives Detection business in 2002 and held various positions over the years, including senior vice president and president of Laboratory Products. Prior to that, he was vice president of sales and marketing for Tyco International.


 











Jul 20, 2017


Mark Stevenson

Mark Stevenson has been promoted to executive vice president and chief operation officer of Thermo Fisher Scientific, effective August 1. In his new role, he will oversee operations of the company's Laboratory Products and Analytical Instruments businesses, in addition to the Life Sciences Solutions business. Since 2014, when Thermo Fisher acquired Life Technologies, Stevenson has been executive vice president and president of Life Sciences Solutions. Prior to that, he was president and chief operating officer of Life Technologies, and before that, he was president and COO of Applied Biosystems.


 











Jul 19, 2017


Hans Bishop

Hans Bishop has been elected to Agilent's board of directors. Bishop is cofounder, president, and CEO of Juno Therapeutics, a Seattle-based biopharmaceutical company. He has also held a range of executive positions in the pharmaceutical industry, including as COO at Dendreon; president of Specialty Medicine at Bayer Healthcare; and global commercial head for Chiron.


 











Jul 19, 2017


Daniel Sikkema

Quanterix has appointed Daniel Sikkema as vice president of acclerator services for the company's new Simoa Accelerator Lab, a dedicated environment for biomarker research, custom assay development, and clinical sample testing. Sikkema will work to expand the reach of Quanterix's Accelerator Lab services in neurology, oncology, immuno-oncology, infectious disease, inflammatory diseases, and other therapeutic areas. He has previously worked at Frontage Lab, Bristol-Myers Squibb, Wyeth, Merck, Sanofi Pasteur, and GlaxoSmithKline.


 











Jul 17, 2017


Stephen Pereira

Stephen Pereira has been appointed to Immunovia's scientific advisory board. Pereira is a professor of hepatology and gastroenterology at University College London and is an honorary consultant in pancreaticobiliary medicine at UCL Hospitals and the Royal Free Hospital. 


 











Jul 17, 2017


Daniel MacArthur

The American Society of Human Genetics has named Daniel MacArthur as the first recipient of its Early Career Award. He is an assistant professor in the Analytic and Translational Genetics Unit at Massachusetts General Hospital and Harvard Medical School and the co-director of the Medical and Population Genetics Program at the Broad Institute. The new award, which comes with $10,000 in prize money, recognizes contributions of genetics and genomics scientists in the first 10 years of their careers as independent investigators. MacArthur and his colleagues developed the Exome Aggregation Consortium (ExAC) database and website and its successor, the Genome Aggregation Database (gnomAD). He also published many scientific articles on identifying genes associated with rare diseases, in particular muscular disorders.


 











Jul 13, 2017


Mary Thistle

Enterome has appointed Mary Thistle to its board of directors as a non-executive director. Thistle currently serves as chief operating officer at Dimension Therapeutics, and has also served as senior VP of Business Development at Cubist Pharmaceuticals. Prior to joining Dimension in 2015, Thistle held leadership positions at ViaCell. In addition to developing therapeutic products for rare and metabolic liver diseases, Enterome also develops diagnostics to support therapies in microbiome-related diseases such as inflammatory bowel disease and cancer.


 











Jul 12, 2017


Arthur Beaudet

The American Society of Human Genetics has named Arthur Beaudet the recipient of this year's Victor A. McKusick Leadership Award. The award recognizes individuals whose "professional achievements have fostered and enriched the development of human genetics as well as its assimilation into the broader context of science, medicine, and health." Beaudet, who will receive the award along with a $10,000 prize at the ASHG annual meeting in October, is the Henry and Emma Mayer Professor in the Department of Molecular and Human Genetics and the Department of Pediatrics at Baylor College of Medicine. He is a member of the National Academy of Medicine and the National Academy of Sciences and has received several other awards for his work. Beaudet has published more than 350 articles in the scientific literature. 


 











Jul 12, 2017


Kári Stefánsson

The American Society of Human Genetics has named Kári Stefánsson the winner of this year's William Allan Award, a prize established in 1961 that recognizes a scientist for "substantial and far-reaching scientific contributions to human genetics." Stefánsson is the founder of Iceland's Decode Genetics, which has conducted a large-scale population genetics research project in Iceland. He has published more than 500 articles in the scientific literature and has received several awards for his work, including the European Society of Human Genetics Award in 2009.


 











Jul 07, 2017


Matthias Raquet

Oneservice, a Swiss company offering complete managed service solutions, consulting, and learning for the life science, diagnostics, and medical device industries, has appointed Matthias Raquet as CEO. Raquet joins Oneservice from Qiagen, where he has worked since 2001, most recently as vice president and head of global service solutions and global customer management. Prior to Qiagen he worked in various management roles at Amersham Pharmacia.


 






 















Breaking News 

  



Fluidigm, Ascendas Genomics Ink MDx Development Pact in China  








Cancer Dependency Maps Developed by Two Research Teams  








Error-Prone DNA Repair Implicated in Analysis of Cancer Mutation Signature Clusters  








Ancient Genome Sequences Point to Canaanite Ancestry in Present-Day Lebanese Population  








Qiagen Q2 Revenues Grow 4 Percent; Firm Nudges Up Full-Year Guidance  








Biomatrica Gets CE-IVD Marks for Sample Collection Tubes  




 
 





 







The Scan 







Embryos Edited in US 

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.



 









True Blue 

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.



 









All the Plants 

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.



 









This Week in Nature 

In Nature this week: a Danish reference genome, and more.



 






 





 











 





 





 












Sponsorships 





 





 





 





 





 





 









 






About us
Advertise
Contact
Jobs
Subscribe







Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved. 





 













































People in the News: Heinrich Dreismann, Harry Glorikian, Mary Alice McMorrow, Gerald Cox, and More | GenomeWeb



















Skip to main content



 







 





 









RSS Feeds
Twitter
LinkedIn
 





 







Log in




Join now


 






Business & PolicyBusiness News
Research Funding
Policy & Legislation
Regulatory News
Reimbursement

TechnologyMicroarrays & Multiplexing
PCR
Informatics
Sequencing
Mass Spec
Sample Prep
Gene Silencing/Gene Editing

ResearchGenetic Research
Gene Expression Research
Epigenetics Research
Proteomics & Protein Research
Cell Biology Research

DiagnosticsMolecular Diagnostics
Companion Diagnostics
Biomarker Discovery & Validation
Drug Discovery & Development
Clinical Sequencing
Clinical Proteomics

Disease AreasCancer
Infectious Disease
Cardiovascular Disease
Neurological & Psychological Disease
Metabolic Disease
Autoimmune Disease
Inherited Disease
Reproductive Health

Applied Markets
ResourcesWebinars
White Papers
The Scan
Career Blog
Job Listings
New Products
People in the News
Conferences & Events


Main menu 






Enter your keywords 





 





Home » People in the News: Heinrich Dreismann, Harry Glorikian, Mary Alice McMorrow, Gerald Cox, and More 

















People in the News: Heinrich Dreismann, Harry Glorikian, Mary Alice McMorrow, Gerald Cox, and More

Oct 07, 2016


 | 

staff reporter


 



Heinrich Dreismann and Harry GlorikianIn a filing with the US Securities and Exchange Commission, Interpace Diagnostics announced the resignations of Heinrich Dreismann and Harry Glorikian from the company's board of directors. The company stated that neither resignation was due to a disagreement with the company or matters relating to the company's operations, policies, or practices.Mary Alice McMorrow



Get the full story
This story is free for registered users
Registering provides access to this and other free content.
Register now.
Already have an account?Login Now.
 













 












Breaking News 

  



Fluidigm, Ascendas Genomics Ink MDx Development Pact in China  








Cancer Dependency Maps Developed by Two Research Teams  








Error-Prone DNA Repair Implicated in Analysis of Cancer Mutation Signature Clusters  








Ancient Genome Sequences Point to Canaanite Ancestry in Present-Day Lebanese Population  








Qiagen Q2 Revenues Grow 4 Percent; Firm Nudges Up Full-Year Guidance  








Biomatrica Gets CE-IVD Marks for Sample Collection Tubes  




 
 





 







The Scan 







Embryos Edited in US 

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.



 









True Blue 

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.



 









All the Plants 

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.



 









This Week in Nature 

In Nature this week: a Danish reference genome, and more.



 






 





 











 





 





 












Sponsorships 





 





 





 





 





 





 









 






About us
Advertise
Contact
Jobs
Subscribe







Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved. 





 


























Myriad Genetics Inc (MYGN) Director DREISMANN HEINRICH's Insider Stock Buys and Sells 



























Home




 Homepage


 Membership Levels


 Membership Data Coverage


 Complete Stock List


 Founder's Message


 The Book


 FREE Trial






Screeners


Value Screens 


 All-In-One Screener


 Industry Overview


 Ben Graham Net-Net


 Undervalued Predictable


 Buffett-Munger Screener


 Magic Formula (Greenblatt)


 Historical Low P/S List


 Historical Low P/B List


 Peter Lynch Screen


 High Short Interest


 52-Week/3Y/5Y Lows


 52-Week/3Y/5Y Highs


 Predictable Companies


 S&P 500 Grid


 Dividend Stocks


 Spin Off List




Downloads | Tools


  Excel Add-In GURUF


 Manual of Stocks™


 Download Financial Data


 Download Guru Portfolios


 Download Stock PDFs


 Download Insider Data


  API


 Mobile App




Strategies


 Performances


 Buffett-Munger


 Undervalued Predictable


 Low P/S


 Low P/B


 Broadest Owned


 Most Weighted






Gurus




 Latest Guru Picks


 Real Time Picks


 List of Gurus (Personalize)


 Gurus Portfolios


 Scoreboard


 Top 10 Holdings View


 Sector Picks


 International Picks


 Aggregated Portfolio


 Consensus Picks


 Guru Bargains


 Hot Picks


 Industry Trends


 Geographic Trend


 ETFs


 Options


 European Shorting






Insiders




 All Insiders


 CEO Buys/Sales


 CFO Buys/Sales


 Insider Cluster


 Guru+Insider Double Buys


 Triple Buys/Sales


 Insider Trends


 Canadian Insider


 Dutch Insider






Market


Market Valuation


 Economic Data


 Industry Overview


 Market-Cap/GDP Valuation


 Global Market Valuation


 Shiller P/E


 Shiller P/E By Sectors


 Buffett Assets Allocation




By Country


 USA


 Australia


 Canada


 China


 Germany


 India


 Japan


 UK


 More...






Articles


Articles


 Editor's Picks


 GuruFocus Research


 Value Ideas


 Interviews with Gurus


 Top Ranked


 Value Idea Contest


 Videos


 Following Authors




Submit Articles


 Writers Wanted


 Value Contest Winners


 Submit Articles Online


 My Articles






Conference




 Value Conference


 Speakers


 Location/Venue


 Register


 After Conference Gathering (Free Drinks)






Tutorials




 Tutorials & Webinars


 FAQ


 Contact Us






Log In




 Free Sign-up


 Log In


 7-Day Free Trial 






Subscribe




 Free Trial ($399/Year)


 Refer a Friend & Earn $50














Search
Compare

Search ▾










Get 7-Day Free Trial



My Portfolios▾

Portfolios Overview
Create New Portfolio
Portfolio Contest


My Gurus▾

Quick Browse
Personalize

My Gurus

Premium Gurus 
Premium Plus Investors 





















SummaryCanadian Dutch CEO Buys CFO Buys Insider Cluster Buys Double Buys Triple Buys Data Export Trend  




Saved!




USA

Canada

UK/Ireland

Europe

Asia

Oceania

Latin America

Africa



Currently Selected:



Show All Countries ▾





Purchase to select this region

Purchase $399
USA

OTCPK
NAS
NYSE
ARCA
OTCBB
AMEX
BATS




Purchase to select this region

Purchase $289
Canada

TSXV
TSX
XCNQ




Purchase to select this region

Purchase $269
UK/Ireland

UK




Purchase to select this region

Purchase $399
Europe

Germany
France
Poland
Russia
Sweden
Turkey
Bosnia and Herzegovina
Italy
Luxembourg
Switzerland


Belgium
Greece
Norway
Spain
Denmark
Bulgaria
Netherlands
Romania
Finland
Serbia
Austria
Croatia
Portugal
Slovakia
Cyprus
Macedonia
Slovenia
Ukraine
Hungary
Lithuania
Latvia
Malta
Iceland
Estonia
Czech Republic

All Countries ▾



Purchase to select this region

Purchase $399
Asia

India
Japan
Korea
Thailand
Hongkong
China
Taiwan
Malaysia
Singapore
Israel


Indonesia
Pakistan
Vietnam
Philippines
Sri Lanka
Kuwait
Nepal
Saudi
Jordan
Oman
Iran
Iraq
United Arab Emirates
Kazakhstan
Bahrain

All Countries ▾



Purchase to select this region

Purchase $269
Oceania

Australia
New zealand




Purchase to select this region

Purchase $299
Latin America

Brazil
Mexico
Argentina
Chile
Peru
Columbia
Jamaica
Venezuela
Ecuador




Purchase to select this region

Purchase $249
Africa

South Africa
Egypt
Nigeria
Mauritius
Morocco
Zimbabwe
Kenya
Tunisia
Ghana
Côte d'Ivoire




 Set As Default







Insider Trades


Try Insider Screener



Myriad Genetics Inc (MYGN) Director DREISMANN HEINRICH's Insider Stock Buys and SellsTo find out why GuruFocus thinks data on insider trades is interesting, read

Can Aggregated Insider Trading Activities Predict the Market?
Stocks That Both Gurus and Insiders Are Buying
Can Aggregated Insider Trading Activities Predict the Market of Different Sectors?




Filter by:



  Default





Search Insider Trade:




Go




Select to drill down:


All Market CapMicro Cap Small Cap Mid Cap Large Cap Mega Cap S&P 500 Companies All SectorsBasic Materials Consumer Cyclical Financial Services Real Estate Consumer Defensive Healthcare Utilities Communication Services Energy Industrials Technology   Display Those with At Least
100 500 1,000 2,000 5,000 10,000 20,000 50,000 100,000  Shares Display Stocks That are within Please Select 1% 
2% 
3% 
4% 
5% 
8% 
10% 
 of Please Select 52-Week Low3-Year Low5-Year LowReal time insider type:BuySellInsider Sentiment Chart 


 Recent Filings Activity
 

Total Records: 769297   Page:1  2   3   4   5   6   7   8   9   10   LAST (25644) 30 per page ▾ 10 20 2530 50 100



Symbol
Company
Insider
Position
Date
Buy/Sell
Shares
Trade Price ($)
Cost ($1000)
Price ChangeSince Trade (%)
Yield (%)
P/E
Market Cap ($M)
Details

MYGNMyriad Genetics...DREISMANN HEINRICHDirector2015-11-05Sell60,000$44.442666.4-47.21
0.0052.131598.059 Link

MYGNMyriad Genetics...DREISMANN HEINRICHDirector2014-02-18Sell30,000$351050-32.97
0.0052.131598.059 Link

MYGNMyriad Genetics...DREISMANN HEINRICHDirector2013-05-10Sell30,000$31.16934.8-24.71
0.0052.131598.059 Link
Total Records: 769297   Page:1  2   3   4   5   6   7   8   9   10   LAST (25644) 30 per page ▾ 10 20 2530 50 100Add this list into my watchlist/portfolio:

1. Add or remove tickers (Comma separated, up to 500 symbols)
MYGN





2. Select destination portfolioYou need to log in to proceed
3. Click the button to finish
 


Related News and Stories: M: comment on M 07-10-2017M: comment on M 06-16-2017M: stocknote 05-11-2017M: comment on M 05-11-2017M: stocknote 05-11-2017M: comment on M 04-02-2017M: comment on M 02-28-2017M: comment on M 02-12-2017M: https://www.libraryf 02-12-2017M: FUN 01-08-2017M: comment on M 01-04-2017M: momentalne je nad ly 01-03-2017M: comment on M 12-11-2016M: Note of M 09-09-2016M: Note of M 08-02-2016 Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company. 


 



Select portfolio(s):








                        Create a new portfolio



Why you are interested?



            Your selection and notes will be stored in your portfolio.
        


Login to add portfolio















Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
                    | Earn affiliate commissions by embedding GuruFocus Charts

                                                GuruFocus Affiliate Program: Earn up to $400 per referral.  ( Learn More) 













Home  About   Jobs    Advertise    Site Map    Term of Use    Privacy Policy     RSS    Mobile App     Email Alerts    Referral Program    Affiliate Program    FAQ    Contact Us
                               

                © 2004-2017                GuruFocus.com, LLC. All Rights Reserved.
            


                    Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC.



                    Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.


















GF Chat {{numOfNotice}}




























×
Manage BookMarks





Close








FEEDBACK

















DREISMANN HEINRICH Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      DREISMANN HEINRICH
                    

•   DANVILLE, CA
                      
How do I update this listing?




                                             Dreismann Heinrich is based out of Danville.   
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from DREISMANN HEINRICH, enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




dreismann heinrich


4253 GOLDEN OAK CT

DANVILLE
CA
                                                        
                                                    94506









Recent SEC Filings




4 filed on 12/01/2016
4 filed on 12/07/2015
4 filed on 11/05/2015
4 filed on 12/04/2014
4 filed on 02/20/2014
4 filed on 12/06/2013
4 filed on 05/10/2013
4 filed on 12/05/2012
4 filed on 12/02/2011
















Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free

















